Thin
Manufactured under strict cGMP-compliant systems at our Hangzhou production base, integrating multi-ton chemical synthesis capacity with rigorous RP-HPLC purification and MS batch verification.
Understanding the physiological cascades, hydrophobic aggregation pathways, and solid-phase synthesis hurdles that define high-purity Beta-Amyloid manufacturing for global drug discovery.
The 42-amino acid isoform (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) contains two extra hydrophobic amino acids (Ile41 and Ala42) compared to Aβ 1-40. This hydrophobic C-terminal extension significantly lowers thermodynamic stability in solution, accelerating spontaneous nucleation into neurotoxic soluble oligomers, protofibrils, and insoluble cross-β sheet fibrils.
Amyloid Beta 1-40 constitutes roughly 80-90% of total circulating cerebrospinal fluid (CSF) and plasma amyloid species. Although significantly less prone to rapid nucleation than Aβ42, measuring the stoichiometric Aβ42/Aβ40 ratio via high-resolution immunoassays or IP-LC-MS/MS provides the definitive clinical biomarker for preclinical Alzheimer's diagnosis.
Post-translationally modified Aβ variants, notably N-terminally truncated pyroglutamate-3 Aβ (AβpE3-42) and Aβ 25-35, exhibit enhanced structural hydrophobicity, resistance to proteolytic degradation by neprilysin, and accelerated synaptic toxicity. Developing synthetic surrogates requires specialized cyclization chemistry and customized protecting group strategies.
In standard academic and preclinical pharmaceutical settings, over 65% of experimental discrepancies in Aβ cytotoxicity assays (MTT, LDH) and binding affinities (SPR, BLI) stem from pre-aggregated peptide starting material. Thinheal implements proprietary Hexafluoroisopropanol (HFIP) and Ammonium Hydroxide counter-solvent treatments followed by precision freeze-drying to guarantee that global researchers receive truly monomeric, unseeded Amyloid Beta lyophilized powder with zero residual seeding cores.
Hangzhou Thinheal Pharma-Tech Co., Ltd. combines advanced chemical synthesis engineering with an integrated raw material supply chain to deliver commercial peptide APIs and custom neurobiology sequences at unrivaled economy of scale.
Synthesizing difficult sequences like Amyloid-β 1-42 is notorious for on-resin intermolecular β-sheet folding, causing incomplete coupling. Our facility utilizes automated microwave-assisted Fmoc-SPPS and pseudoproline (oxazolidine) dipeptides at positions Gly25-Ser26 and Gly29-Ala30, completely disrupting peptide chain aggregation during elongation.
Downstream purification of Amyloid Beta demands extreme chromatographic selectivity. Thinheal employs DAC (Dynamic Axial Compression) columns (up to 300 mm internal diameter) packed with C18 and C4 spherical silica matrices, utilizing dual-phase gradient elution (aqueous acetonitrile with ammonium acetate or dilute TFA) to achieve baseline separation from closely related diastereomers.
Every commercial batch leaving Hangzhou Thinheal is accompanied by a cGMP-aligned technical release dossier. Sourcing organizations receive unedited Analytical Certificates (CoA) including analytical RP-HPLC traces, ESI-MS or MALDI-TOF mass spectrometry, net peptide content quantification, residual solvent headspace GC, and bacterial endotoxin (LAL) validation.
The regulatory approval and clinical validation of anti-amyloid monoclonal antibodies (such as Lecanemab and Donanemab) have catalyzed unprecedented global demand for high-grade synthetic Amyloid peptides across target validation, bioassays, and diagnostic calibration.
Following FDA and EMA authorizations for disease-modifying therapies, global biopharma sponsors and CROs are accelerating candidate screening for next-generation antibodies, scFvs, nanobodies, and peptide-drug conjugates (PDCs). Recombinant and synthetic Aβ1-42 protofibrils are essential substrates for establishing epitope kinetics and off-target binding profiling.
The transition from invasive CSF lumbar punctures and costly Amyloid PET imaging to blood plasma diagnostics (measuring p-Tau181, p-Tau217, and Aβ42/Aβ40 ratios) is exploding. Diagnostic kit manufacturers require metric tons of ultra-pure synthetic Aβ standards to establish baseline standard curves across high-sensitivity platforms (SIMOA, ECLIA, mass spec).
Academic institutions and biotech accelerators are heavily exploring small-molecule chaperones, PROTAC degrader molecules, and covalent modifiers engineered to bind monomeric Aβ or disassemble early toxic oligomeric intermediates. Sourcing uninhibited monomeric Aβ with predictable lag-phase Thioflavin T (ThT) kinetics is vital for screening campaigns.
Below is our standardized catalog pricing matrix for high-purity Beta-Amyloid peptide standards and functional analogues. Custom bulk quantities (up to multi-kilograms) are quoted individually via our regional pharmaceutical export desks.
| Peptide Variant / Product | CAS Number | Molecular Weight | HPLC Purity | Standard Pack Tier | Reference Price (USD) | Supply Lead Time |
|---|---|---|---|---|---|---|
| Amyloid Beta 1-42 (Human) | 107761-42-2 | 4514.10 Da | ≥95% / ≥98% | 1 mg / 5 mg / 25 mg | $120 / mg (Tier Discounts) | In Stock (Global 3-5 Days) |
| Amyloid Beta 1-40 (Human) | 131438-79-4 | 4329.86 Da | ≥95% / ≥98% | 1 mg / 10 mg / 50 mg | $75 / mg (Bulk custom) | In Stock (Global 3-5 Days) |
| Amyloid Beta 25-35 (Neurotoxic Core) | 131602-53-4 | 1060.27 Da | ≥95% | 5 mg / 25 mg / 100 mg | $35 / mg | In Stock (Global 3-5 Days) |
| Amyloid Beta pE3-42 (Pyroglutamate) | N/A (Modified) | 4309.84 Da | ≥95% | 0.5 mg / 1 mg / 5 mg | $220 / mg | Custom Synthesis (2-3 Wks) |
| FITC-Amyloid Beta 1-42 (N-Terminal) | N/A (Labeled) | 4885.50 Da | ≥95% | 0.5 mg / 1 mg / 5 mg | $180 / mg | In Stock (Global 3-5 Days) |
| Scrambled Amyloid Beta 1-42 (Control) | N/A (Random) | 4514.10 Da | ≥95% | 1 mg / 5 mg | $135 / mg | In Stock (Global 3-5 Days) |
| Amyloid Beta 1-42 (Rat / Mouse) | 107761-41-1 | 4418.01 Da | ≥95% | 1 mg / 5 mg | $140 / mg | In Stock (Global 3-5 Days) |
| Custom Peptide APIs (e.g. Semaglutide/TB500) | Diverse (e.g. 910463-68-2) | Varies | ≥99.0% cGMP | 100 g / 1 kg / Multi-ton | Request CDMO Quotation | Commercial Campaign Scale |
* Note: Prices reflect baseline institutional research-grade specifications (trifluoroacetate salt). Inquire for acetate salt exchange, specific endotoxin limits (<0.05 EU/mg), custom isotopic labeling (15N/13C), or cGMP validation campaigns.
Standardizing the reconstitution, dissolution, and fibril induction stages is indispensable to generating peer-reviewed, reproducible experimental endpoints across clinical neuroscience.
Treat lyophilized Aβ powder with ice-cold 100% 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) at 1 mg/mL. Incubate at room temperature for 1–2 hours to disassemble pre-existing quaternary aggregates. Evaporate the HFIP under a gentle stream of nitrogen or centrifugal vacuum concentrator to yield an ultra-clear peptide film. Store dessicated at -80°C.
Resuspend the monomerized peptide film in dry anhydrous DMSO to 5 mM; vortex thoroughly and sonicate in an ice-water bath for 10 minutes. Dilute immediately with ice-cold phenol-red free cell culture media (Ham's F12 or Neurobasal) to a working concentration of 100 µM. Incubate statically at 4°C for 24 hours to promote stable globular oligomer formation (12-mers to 24-mers).
To produce fibrillar aggregates for amyloid plaque mimicking or antibody avidity assays, dissolve the film in 10 mM PBS buffer (pH 7.4) to 50–100 µM. Incubate at 37°C under continuous orbital shaking (300 rpm) for 48–72 hours. Measure the dramatic enhancement of ThT fluorescence emission at 485 nm (excitation 440 nm) to quantify the sigmoid aggregation curve.
Peptide synthesis at commercial volume necessitates absolute control over counter-ions, racemization, deletion peptides, and cold-chain stability.
Residual Trifluoroacetate (TFA) anions remaining after HPLC cleavage act as potent neurotoxins in cell cultures, skewing in vitro primary neuron viability assays and cellular metabolism measurements. Thinheal offers verified ion-exchange protocols substituting TFA with biocompatible acetate or ammonium counter-ions, depressing residual TFA levels below 0.1% or non-detectable thresholds.
During the challenging coupling of His6, His13, and His14, optical purity is preserved using ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma Pure) and diisopropylcarbodiimide (DIC) at controlled cryogenic temperatures. Furthermore, to prevent spontaneous oxidation of Methionine-35 into Met(O)-Aβ (which drastically retards fibrillization), all synthesis and lyophilization cycles occur under inert argon purging.
Lyophilized Amyloid Beta is inherently hygroscopic and susceptible to humidity-driven solid-state seeding at ambient temperatures. Thinheal guarantees cold-chain packaging utilizing vacuum-sealed, amber borosilicate glass vials cushioned in dry ice containers with integrated continuous temperature loggers, ensuring uninterrupted shipment integrity to North America, Europe, and Asia-Pacific.
Strategic sourcing directors and analytical heads follow a rigid six-point qualification audit when evaluating peptide API manufacturing partners in China.
A simple stated nominal mass is insufficient. Qualified buyers require high-resolution ESI-Q-TOF or Orbitrap MS data confirming deconvoluted molecular mass matching theoretical exact mass within ±0.2 Da. For long peptides like Aβ1-42, isotopic distribution matching and peptide mapping prove absence of isobaric amino acid substitutions.
Raw HPLC purity % must be accompanied by comprehensive integration chromatograms showcasing UV absorption at 214 nm and 280 nm. Procurement teams inspect the presence of diastereomers, deletion sequences, and beta-sheet aggregates that elute close to the main product peak, ensuring specified purity represents true API content.
Because lyophilized peptides contain residual moisture, counter-ions, and bound salts, net peptide content typically ranges from 70% to 85% of total cake mass. Thinheal performs quantitative Amino Acid Analysis (AAA) or elemental Nitrogen analysis to establish accurate peptide content, allowing formulation teams to dose by exact active peptide molarity.
Biopharmaceutical sponsors demand dual-source supply security. Operating both an advanced R&D center and an industrial-scale manufacturing plant in Hangzhou, Thinheal maintains continuous synthesis lines for metabolic peptides (Semaglutide, Mazdutide, Orforglipron) and neurodegenerative tools, preventing global supply interruptions.
Explore our validated therapeutic analogues, metabolic disease APIs, and neuroprotective peptide building blocks manufactured for global biopharma innovators.
Authoritative, bench-validated answers covering solubility mechanics, aggregation troubleshooting, bulk purchasing, and regulatory release testing.
Amyloid-β 1-42 features a strong hydrophobic core (residues 17–21, LVFFA) paired with a hydrophobic C-terminus (residues 29–42, GAIIGLMVGGVVIA). In physiological aqueous buffers at neutral pH, these hydrophobic regions collapse into intermolecular cross-β sheets almost instantaneously, forming insoluble amorphous precipitates rather than transparent isotropic solutions. To achieve complete dissolution, researchers must first treat the dry peptide with HFIP or basic solutions (such as 0.1% NH4OH or dilute 20 mM NaOH) to disrupt intermolecular hydrogen bonds, raising the solution pH above the isoelectric point (~5.3) before buffer neutralization.
Synthetic peptides are typically purified using trifluoroacetic acid (TFA) as an ion-pairing agent during preparative RP-HPLC, leaving residual TFA anions electrostatically paired with basic residues (Arg, Lys, His) and the N-terminal amine. In cell-based viability assays, free TFA ions exhibit non-specific neurotoxicity, impair cell proliferation, and suppress neuronal firing rates. For primary cell cultures, electrophysiology, or in vivo stereotaxic rodent injections, Thinheal strongly advises utilizing our Acetate Exchange Form (<0.1% TFA content) to prevent toxic artifacts.
Variations in the lag phase of Thioflavin T (ThT) fluorescence curves are universally caused by heterogeneous trace seeding aggregates present prior to shipment. Thinheal executes a standardized double-depolymerization protocol using validated volatile organic fluorinated solvents followed by lyophilization under high vacuum (<0.05 mbar). Every commercial lot undergoes analytical quality release including dynamic light scattering (DLS) and ThT kinetics testing to confirm that the starting monomer population is entirely free of pre-seeded nucleation centers.
Yes. By employing extended flexible aminohexanoic acid (Ahx) or PEG-linkers between the fluorescent moiety (e.g., FITC, 5-FAM, Cy5, or Biotin) and the N-terminal Asp1 residue, the fluorophore is spatially segregated from the primary aggregation-driving hydrophobic core (residues 17–42). This strategic design maintains standard oligomerization kinetics and membrane binding characteristics while providing brilliant excitation/emission profiles for confocal fluorescence microscopy, flow cytometry, and ligand-receptor binding assays.
Research Use Only (RUO) peptides focus on sequence fidelity, high purity (>95%), and rapid synthesis turnaround for discovery-stage in vitro studies. In contrast, cGMP-grade manufacturing (applicable to therapeutic clinical APIs like Semaglutide or Thymosin α1) operates under rigid quality systems: validated cleaning and process routines, dedicated environmental cleanrooms (Class D to A), fully traceable pharmacopoeia-grade raw materials, ICH Q7 guidelines, full electronic audit trails, validated stability studies, and formal Drug Master File (DMF) regulatory submissions.
Our international export department maintains four specialized regional desks covering North America, Europe, CIS, and the Asia-Pacific region. Orders are packaged in sealed cryo-vials with thermal phase-change packs or dry ice to avoid freeze-thaw degradation during international transit. We coordinate all customs Harmonized System (HS) classifications (Code: 2937190000) and regulatory export compliance documentation to guarantee smooth clearing, typically delivering to US and European client laboratories within 3 to 5 business days after batch release.
Whether you require 10 mg of monomeric Amyloid Beta 1-42 for academic screening or kilograms of cGMP therapeutic APIs (GLP-1 analogues, Thymosin, or bespoke CDMO campaigns), Hangzhou Thinheal Pharma-Tech Co., Ltd. provides direct manufacturing capability with transparent factory pricing.